ALLMedicine™ Unstable Angina Center

Aug 5th, 2020 - The high-purity eicosapentaenoic acid (EPA) prescription fish oil-derived omega-3 fatty acid (omega-3), icosapent ethyl (IPE), was recently approved by the United States Food and Drug Administration (FDA) for cardiovascular disease (CVD) preventio...

Aug 4th, 2020 - Despite the use of high-sensitive cardiac troponin there remains a group of high-sensitive cardiac troponin negative patients with unstable angina with a non-neglectable risk for future adverse cardiovascular events, emphasising the need for addit...

Jul 28th, 2020 - Purpose: Acute coronary syndrome presents as unstable angina (UA) or acute myocardial infarction (AMI). We explored the use of exosomal miR-122-5p as a biomarker for UA and AMI and determined whether its expression level is positively correlated w...

Jul 16th, 2020 - In patients with unstable angina pectoris (UAP) or non-ST elevation myocardial infarction (NSTEMI), long-term mortality remains high despite improvements in the diagnosis and treatment. In this study, we investigated whether serum albumin level is...

Jul 15th, 2020 - This study was designed to investigate the effects of leukocyte Rho kinase activity and serum Cystatin C (Cys C) on cardiovascular events in patients with acute coronary syndrome (ACS). A total of 48 patients with ST-segment elevation myocardial i...

Jun 14th, 2019 - Purpose: To review the evidence and provide clinical recommendations for the screening and treatment of depression in patients who have had a recent acute coronary syndrome event. Methods: This guideline is based on a systematic review of randomi...

Apr 25th, 2019 - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Praluent® (alirocumab) to reduce the risk of heart attack, stroke and unstable angina requiring hospitalization...

Feb 28th, 2019 - LDL cholesterol (LDL-C) reduction with statins and PCSK9 inhibitors reduces risk of myocardial infarction (MI), but effects on specific types of MI are unknown. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab (ALI) with placebo (PBO) in 1...

Feb 28th, 2019 - Background In time-to-first-event analyses, icosapent ethyl significantly reduced the risk of ischemic events, including cardiovascular death, among patients with elevated triglycerides receiving statins. These patients are at risk for not only fi...

Oct 31st, 2014 - These guidelines are intended to apply to adult patients with stable known or suspected ischemic heart disease (IHD), including those with new-onset chest pain (i. e.

Aug 5th, 2020 - The high-purity eicosapentaenoic acid (EPA) prescription fish oil-derived omega-3 fatty acid (omega-3), icosapent ethyl (IPE), was recently approved by the United States Food and Drug Administration (FDA) for cardiovascular disease (CVD) preventio...

Aug 4th, 2020 - Despite the use of high-sensitive cardiac troponin there remains a group of high-sensitive cardiac troponin negative patients with unstable angina with a non-neglectable risk for future adverse cardiovascular events, emphasising the need for addit...

Jul 28th, 2020 - Purpose: Acute coronary syndrome presents as unstable angina (UA) or acute myocardial infarction (AMI). We explored the use of exosomal miR-122-5p as a biomarker for UA and AMI and determined whether its expression level is positively correlated w...

Jul 16th, 2020 - In patients with unstable angina pectoris (UAP) or non-ST elevation myocardial infarction (NSTEMI), long-term mortality remains high despite improvements in the diagnosis and treatment. In this study, we investigated whether serum albumin level is...

Jul 15th, 2020 - Clopidogrel tablets are P2Y 12 platelet inhibitor indicated for: ●  Acute coronary syndrome – For patients with non–ST-segment elevation ACS (unstable angina [UA]/non–ST-elevation myocardial infarction [NSTEMI]), clopidogrel tablets have been show...

Aug 26th, 2019 - Patients at the highest risk derived the most benefit from aggressive lipid-lowering with PCSK9 inhibition, according to two analyses of the ODYSSEY OUTCOMES trial. Investigators previously showed that people randomized to receive alirocumab (Pral...

Aug 12th, 2019 - Adding electrocardiogram findings and clinical assessment to high-sensitivity cardiac troponin measurements in patients presenting with chest pain could improve predictions of their risk of 30-day major adverse cardiac events, particularly unstabl.

Aug 5th, 2019 - Strokes occurring after percutaneous coronary intervention (PCI) have become a worrisome trend, according to U.S. data. From 2003 to 2016, adjusted stroke rates were on the upswing following PCI for all indications (P<0.001 for all): ST-segment el...

Jul 17th, 2019 - Combination lipid-lowering therapy may be especially effective among older acute coronary syndrome (ACS) survivors, a group that had no safety issues with simvastatin/ezetimibe (Vytorin) in the IMPROVE-IT trial. Across age groups, patients randomi...

Jun 14th, 2019 - Purpose: To review the evidence and provide clinical recommendations for the screening and treatment of depression in patients who have had a recent acute coronary syndrome event. Methods: This guideline is based on a systematic review of randomi...